All Articles

On May 26, 2020, the FDA approved a new indication for the combination of the PD-1 inhibitor Opdivo (nivolumab) and the CTLA-4 inhibitor Yervoy (ipilimumab; both from Bristol Myers Squibb) plus 2 cycles only of chemotherapy as the first-line treatment of patients with recurrent or metastatic non–small-cell lung cancer (NSCLC), including patients with squamous or nonsquamous NSCLC, regardless of PD-L1 expression, and no EGFR or ALK genomic aberrations. Read More ›

COVID-19 has brought virtual learning into the mainstream, meaning that a child with cancer who learns from home is now in the same “classroom” environment as any other student, which can reduce feelings of stress and anxiety. Read More ›

Dive into this special issue focused on immunotherapy, the innovative methods of treating cancer today, with this introduction by Lillie Shockney, RN, BS, MAS, HON-ONN-CG. Read More ›

Laurie Adami chronicles her long fight with follicular lymphoma, including her run-in with 6 types of therapies. After losing all hope, she finally achieved complete remission with a new immunotherapy called CAR T-cell therapy, and then turned her sights on climbing Mt. Everest to raise money for cancer research. Read More ›

Not sure what immunotherapy is and how it works? Read about the cellular mechanism and the various types of immunotherapies, including those that use your own immune system to destroy cancer cells. This article also addresses the side effects of immunotherapy. Read More ›

Cutaneous squamous-cell carcinoma (CSCC), or skin cancer, is the second most common cancer in the United States. This article examines the results of a recent study on the first and only immunotherapy approved for patients with advanced or metastatic CSCC. Read More ›

About 15% of lung cancers are small-cell lung cancer, and about one-third of those are extensive-stage small-cell lung cancer. In March 2020, the FDA approved the first immunotherapy, for use with chemotherapy, for first-line treatment of patients with extensive-stage small-cell lung cancer. Read More ›

A new study was presented at the 2020 ASCO meeting that compared, for the first time, the use of immunotherapy versus chemotherapy for treating patients with metastatic colorectal cancer and microsatellite instability-high or mismatch repair-deficient abnormalities. Read More ›

This article discusses findings from a clinical trial showing that Keytruda prolongs the time without disease progression in patients with relapsed or refractory classical Hodgkin lymphoma compared with the current standard of therapy. Read More ›

In May 2020, the FDA approved the combination of 2 immunotherapies for patients with metastatic hepatocellular carcinoma (liver cancer) who have not received systemic therapy and cannot be treated by surgery. Read More ›